Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration to Discover Novel Therapies for Autoimmune and Inflammatory Diseases
核心洞察
Evotec SE and Odyssey Therapeutics have entered a strategic R&D collaboration to discover new small molecule treatments for autoimmune and inflammatory diseases (搜索).
Odyssey will leverage Evotec's AI-enabled discovery platform, advanced screening capabilities, and proprietary compound libraries to identify validated hit series across multiple high-value targets.
The collaboration combines high-throughput experimentation with machine learning-driven analysis to accelerate early-stage research and advance promising therapeutic programs.
Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) and Odyssey Therapeutics, Inc. (搜索) (NASDAQ: ODTX) announced on August 6, 2026, that they have entered a strategic R&D collaboration aimed at discovering potential new treatments in autoimmune and inflammatory diseases (搜索). The partnership brings together Odyssey's deep expertise in autoimmune and inflammatory disease biology with Evotec's integrated, AI-enabled drug discovery platform to accelerate the identification of differentiated small molecule drug candidates.
Under the terms of the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities, and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets. The collaboration is designed to accelerate the identification of validated hit series and enable the rapid progression of promising therapeutic programs with the potential to transform the standard of care in large inflammatory and autoimmune diseases with high unmet medical need.
Integrating AI and Disease Biology
The collaboration combines high-throughput experimentation with machine learning-driven analysis, reflecting the growing role of artificial intelligence in modern drug discovery. By uniting complementary scientific and technological strengths, the companies aim to efficiently generate and advance new medicines from early-stage research through to validated starting points for further development.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the strategic importance of the collaboration: "Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches to drug discovery. This collaboration with Odyssey illustrates well Evotec's strategy in applying integrated discovery platform technologies to complex disease areas where new approaches are urgently needed. Together, we aim to generate differentiated and validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases (搜索)."
Financial Structure and Strategic Alignment
Evotec is eligible to receive milestone payments based on the successful delivery of validated hit series for each target, aligning value creation with successful discovery outcomes. Detailed financial terms were not disclosed. The collaboration underscores both companies' shared commitment to advancing therapies for patients with autoimmune and inflammatory diseases (搜索), areas that continue to represent significant unmet medical need.
Evotec, a life science company with a global team of more than 4,500 experts operating from sites in Europe and the U.S., works with all Top 20 Pharma companies and over 800 biotechs. The company's proprietary platforms span small molecules, biologics, cell therapies, and associated modalities, supported by technologies including Molecular Patient Databases, PanOmics, and iPSC-based disease modeling. Odyssey Therapeutics, trading on NASDAQ under the symbol ODTX, brings focused expertise in autoimmune and inflammatory disease biology to the partnership.